BNET Industries
AstraZeneca Plc. is in the Pharma Industry
Latest News and Analysis
Roche Seen Likely to Raise Bid For Genentech
By Deena Beasley LOS ANGELES (Reuters) - Roche Holding AG ROG may need to raise its $43.7 billion bid for the Genentech Inc DNA stock that it does not already own, but an eventual deal is likely, analysts and investors said on Monday....
Roche Offers to Buy Out Genentech For $43.7 Billion
By Sam Cage BASEL, Switzerland (Reuters) - Swiss drugmaker Roche Holding AG ROG offered to acquire all outstanding shares in its U.S. partner Genentech Inc DNA for $43.7 billion in cash to reinforce its position in cancer medicines. Roche, which already owns 55.9...
Monday Options Outlook: SGP, MRK, AZN, AMGN, CELG, BBH, BAC, KRE, XLF
Rebecca Engmann Darst co-authored this article. Schering-Plough SGP ? Shares are down 11.2% to $19.04 after the company announced that it would postpone its results until after the bell pending the release of new data surrounding its drug Vytorin. Implied volatility shot up 62% to 75.9% on...
Roche Offers to Buy Out Genentech
By Sam Cage BASEL, Switzerland (Reuters UK) - Swiss drugmaker Roche Holding ROG offered to acquire all outstanding shares in its U.S. partner Genentech DNA for $43.7 billion (21.9 billion pounds) in cash to reinforce its position in cancer medicines. Roche, which already owns 55.9...
Dollar, Cost Cuts Help Novartis Q2 Beat Forecast
By Sam Cage ZURICH (Reuters) - Second-quarter net profit at Novartis AG NOVN rose 17 percent to $2.27 billion, helped by the weak U.S. dollar and cost cutting efforts, beating forecasts and boosting its shares. The Swiss drugmaker confirmed its full-year forecast on...
Summary Judgment in Seroquel Case Favors AstraZeneca; Teva and Sandoz to Appeal
Aaron F. Barkoff submits: AstraZeneca v. Teva Pharms. USA and Sandoz, No. 05-5333 (D.N.J. 2008) On July 1, the U.S. District Court for the District of New Jersey granted AstraZeneca's AZN motion for summary judgment that its patent on quetiapine fumarate, the active ingredient in Seroquel, is not unenforceable...
Astrazeneca: Size, Safety and Consistency
The Correct Call submits: Size, safety, and consistency are good attributes to have in this market, and Astrazeneca AZN possesses all three. The company is a pharmaceutical giant that makes such popular drugs as Crestor for cholesterol and Symbicort for asthma. AZN has a market cap of about $68 billion....
How Not to Do An Acquisition: AstraZeneca-MedImmune
When AstraZeneca ponied up more than $15 billion for the biotech MedImmune just over a year ago, the deal suggested that desperate Big Pharmas were willing to open their wallets wide for biotechs without looking too closely into the question of whether they were really worth the money. As I...
Glaxo to Double China R&D Staff in Next Few Years
By Sophie Taylor SHANGHAI (Reuters UK) - GlaxoSmithKline GSK, the world's second-largest drugmaker, plans to double its research and development staff in China to 350 people in the next few years, an executive said on Tuesday. The company currently employs 170 R&D staff in China and...
AstraZeneca Bolstered By Seroquel Patent Victory
By Ben Hirschler LONDON (Reuters UK) - AstraZeneca AZN shares rose nearly 5 percent on Wednesday after the group won a key U.S. patent battle over its second-biggest selling drug, Seroquel, for schizophrenia and bipolar disorder. The court decision to award summary judgment in its favour,...
AstraZeneca Wins Legal Round in Teva Seroquel Row
WASHINGTON (Reuters UK) - Teva Pharmaceutical Industries Ltd TEVA said on Tuesday that AstraZeneca Plc AZN won the latest court battle in their patent dispute over a generic version of AstraZeneca's blockbuster schizophrenia drug. The U.S. District Court for the District of New Jersey granted...
AstraZeneca's Acquisition of MedImmune Still Looks Overpriced
EP Vantage submits: One year on from AstraZeneca’s AZN acquisition of MedImmune for a whopping $15.6bn, the two parties are no doubt conducting a review of how well the integration has progressed. More importantly, investors in the UK group will be looking to see what value the acquisition has added...
MedImmune CEO Quits AstraZeneca
By Ben Hirschler LONDON (Reuters UK) - David Mott, the head of AstraZeneca's AZN MedImmune unit, is to leave the group at the end of July, one year after selling his biotech business to the Anglo-Swedish drugmaker. An AstraZeneca spokesman said on Thursday Mott had decided...
Will Bayer AG Overtake AstraZeneca in China Drug Sales?
ChinaBio Today submits: According to Reuters, Germany's Bayer AG (BYERF.PK) thinks it can become the biggest seller of prescription drugs in China this year, bypassing AstraZeneca (NYSE: AZN), which is currently the top dog. Arthur J. Higgins, the head of Bayer Healthcare, said that revenues in China...
China Biotech Week in Review: Deals and Drugs
ChinaBio Today submits: Last week, the news item that could have the most profound effect on the China biomedical world, did not – paradoxically – involve a China biomedical company. The third largest pharmaceutical company in Japan, Daiichi Sankyo [TSE: 4568.JP], announced its intention to buy a majority stake...
Mylan Prevails Over AstraZeneca in Appeal of Prilosec Case
Aaron F. Barkoff submits: Yesterday, the Court of Appeals for the Federal Circuit affirmed a June 2007 district court decision finding that Mylan's MYL generic version of Prilosec omeprazole does not infringe two AstraZeneca patents AZN, U.S. Patent Nos. 4,786,505 and 4,853,230. Omeprazole is difficult to formulate because...
WuXi PharmaTech Signs on for Three More Years with AstraZeneca
ChinaBio Today submits: WuXi PharmaTech (NYSE: WX) has extended its collaboration with AstraZeneca (NYSE: AZN) for an additional three years. The first collaboration between the two companies, a $14 million two-year agreement begun in 2006, was very successful. During the last two years, using its high throughput...
AstraZeneca Q3 2007 Earnings Call Transcript
AstraZeneca Q3 2007 Earnings Call Transcript
AstraZeneca Q2 2007 Earnings Call Transcript
AstraZeneca Q2 2007 Earnings Call Transcript
Demand-Driven Solution for Production Scheduling Based on SAP Advanced Planning & Optimization
AstraZeneca, one of the world's largest pharmaceutical companies, is an innovator when it comes to supply chain management SCM. The project was driven by the need for greater agility and flexibility in the supply chain process, with the ultimate objectives of enhancing customer service and improving the flow of information...
- Next »
- page 1 of 2
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Noven Pharmaceuticals Inc. (6 results)
- Biotechnology (6 results)
- Rogers Corp. (5 results)
- Biotech (4 results)
- Finance (4 results)
- China (4 results)
- GlaxoSmithKline Plc. (4 results)
- Mergers & Acquisitions (3 results)
- Investment (3 results)
- Strategy (3 results)
- Business Operations (3 results)
- Healthcare (3 results)
- Sales Strategy (3 results)
- Roche Holding AG (3 results)
- Genentech Inc. (3 results)
- Oukbs (3 results)
AstraZeneca Plc. Company Info
NAICS Code
Pharmaceutical Preparation Manufacturing: 325412Brought to you by IBMSponsored Resources
